Abstract
Chemotherapy-induced severe hyponatremia is a life-threatening condition. Platinum-based agents play a key role in ovarian cancer treatment, but they are more likely to cause hyponatremia than other anti-cancer agents. The optimal strategy for treating ovarian cancer in the case of severe hyponatremia induced by the platinum agent remains unclear. We report the case of 77-year-old women with multiple peritoneal recurrences five years and eight months after surgery for ovarian clear cell carcinoma. She received tri-weekly docetaxel and carboplatin (DC) therapy and bevacizumab, following which she developed severe hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Highlights
Hyponatremia occurs in 2.6%-29.1% of patients receiving chemotherapy [1]
We report the case of 77-year-old women with multiple peritoneal recurrences five years and eight months after surgery for ovarian clear cell carcinoma
Carboplatin administration may be a promising alternative to tri-weekly carboplatin administration after the development of carboplatin-induced Secretion of Antidiuretic Hormone (SIADH)
Summary
Hyponatremia occurs in 2.6%-29.1% of patients receiving chemotherapy [1]. platinum-based agents play a key role in ovarian cancer treatment, they are more likely to cause hyponatremia than nonplatinum-based agents (incidence of hyponatremia: 11.9% and 3.8%, respectively) [1]. The optimal strategy for treating ovarian cancer in the case of severe hyponatremia induced by the platinum agent remains unclear. She received tri-weekly docetaxel and carboplatin (DC) therapy and bevacizumab, following which she developed severe hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
